Oxford BioTherapeutics has entered a multi‑year collaboration with Bristol Myers Squibb to discover and develop novel T‑cell ...

Bayer has received MHRA approval for Kerendia (finerenone) for adults in the UK with symptomatic chronic heart failure and a left ventricular ejection fraction of 40% or above. Th ...

Metabolic dysfunction-associated steatotic liver disease, formerly known as non-alcoholic fatty liver disease and often referred to as fatty liver disease, affects nearly 30% of adults worldwide. It ...

GLP-1 therapies have now advanced far beyond their origins. Originally developed as treatments for type 2 diabetes, they have become one of the most influential forces reshaping consumer behaviour, ...

For decades, progress in IVF has been driven by improvements in process efficiency rather than advances in biology. Clinics have become better at retrieving eggs, culturing embryos and selecting those ...

Kainova Therapeutics has dosed the first patient in the European expansion of its DOMISOL phase 1/2 trial of DT 7012, a ...

A British inquiry into the use of chemotherapy to treat seriously ill cancer patients has found the treatment caused or hastened death in 27% of cases. A British inquiry into the use of chemotherapy ...

New study to test Sema3A antibody in rare genetic kidney disease Evotec SE has announced that partner Bayer AG has initiated a phase 2 clinical study of BAY 3401016, a monoclonal antibody targeting ...

Previously the licence referred to “physicians”, prompting confusion over who is able to inject the treatment. Allergan has received a license update for Botox (botulinum toxin type A) in the UK, ...